Ipsen (OTCPK:IPSEY) and Skyhawk Therapeutics Monday reported the signing of an exclusive collaboration to discover and develop novel small molecules that modulate RNA for rare neurological diseases.

Ipsen has expanded its R&D pipeline once again, agreeing a $1.8 billion alliance with Skyhawk Therapeutics focused on the development of RNA-targeting therapies for rare neurological diseases.

The three drug discovery deals are with Convelo Therapeutics in neurological disorders such as multiple sclerosis, Sosei Heptares for G-protein-coupled receptor-targeting compounds, and Skyhawk ...